GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cormedix Inc (STU:19KA) » Definitions » Short-Term Debt

Cormedix (STU:19KA) Short-Term Debt : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cormedix Short-Term Debt?

Cormedix's Short-Term Debt for the quarter that ended in Mar. 2024 was €0.00 Mil.


Cormedix Short-Term Debt Historical Data

The historical data trend for Cormedix's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cormedix Short-Term Debt Chart

Cormedix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cormedix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cormedix Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Cormedix Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Cormedix's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Cormedix (STU:19KA) Business Description

Traded in Other Exchanges
Address
300 Connell Drive, Suite 4200, Berkeley Heights, NJ, USA, 07922
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's primary focus is to develop its lead product candidate, DefenCath, for potential commercialization in the United States (U.S.) and other key markets.

Cormedix (STU:19KA) Headlines

No Headlines